메뉴 건너뛰기




Volumn 92, Issue 1, 2005, Pages 75-82

Chronic myelogenous leukaemia: Recent progress in biology and therapeutic strategies;Leucémie myéloïde chronique: Actualités biologiques et thérapeutiques

Author keywords

Bcr Abl; Chronic myelogenous leukemia; Imatinib mesylate; Tyrosine kinase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ABELSON KINASE; AG 858; ALPHA INTERFERON; AP 234464; BCR ABL PROTEIN; BORTEZOMIB; CYTARABINE; DASATINIB; EVEROLIMUS; FLAVOPIRIDOL; IMATINIB; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VATALANIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

EID: 13744259144     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)

References (31)
  • 1
    • 0141528828 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: Advances in biology and new approaches to treatment
    • Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-64.
    • (2003) N Engl J Med , vol.349 , pp. 1451-1464
    • Goldman, J.M.1    Melo, J.V.2
  • 2
    • 0000286732 scopus 로고
    • A minute chromosome in human chronic granulocytic leukaemia
    • Nowell PH, Hungerford DA. A minute chromosome in human chronic granulocytic leukaemia. Science 1960; 132: 1497.
    • (1960) Science , vol.132 , pp. 1497
    • Nowell, P.H.1    Hungerford, D.A.2
  • 3
    • 0015694748 scopus 로고
    • A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
    • Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-3.
    • (1973) Nature , vol.243 , pp. 290-293
    • Rowley, J.D.1
  • 4
    • 0033614396 scopus 로고    scopus 로고
    • Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta
    • Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan AG, et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 1999; 18: 2676-80.
    • (1999) Oncogene , vol.18 , pp. 2676-2680
    • Canitrot, Y.1    Lautier, D.2    Laurent, G.3    Frechet, M.4    Ahmed, A.5    Turhan, A.G.6
  • 6
    • 0018654774 scopus 로고
    • Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin
    • Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979; 300: 333-7.
    • (1979) N Engl J Med , vol.300 , pp. 333-337
    • Fefer, A.1    Cheever, M.A.2    Thomas, E.D.3    Boyd, C.4    Ramberg, R.5    Glucksberg, H.6
  • 7
    • 0022623818 scopus 로고
    • Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha a in chronic myelogenous leukemia
    • Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Rearing MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065-9.
    • (1986) N Engl J Med , vol.314 , pp. 1065-1069
    • Talpaz, M.1    Kantarjian, H.M.2    McCredie, K.3    Trujillo, J.M.4    Rearing, M.J.5    Gutterman, J.U.6
  • 8
    • 0028283040 scopus 로고
    • Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups
    • McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486-8.
    • (1994) Lancet , vol.343 , pp. 1486-1488
    • McGlave, P.B.1    De Fabritiis, P.2    Deisseroth, A.3    Goldman, J.4    Barnett, M.5    Reiffers, J.6
  • 9
    • 0345696854 scopus 로고    scopus 로고
    • Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
    • French Chronic Myeloid Leukemia Study Group
    • Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-9.
    • (1997) N Engl J Med , vol.337 , pp. 223-229
    • Guilhot, F.1    Chastang, C.2    Michallet, M.3    Guerci, A.4    Harousseau, J.L.5    Maloisel, F.6
  • 10
    • 10744222203 scopus 로고    scopus 로고
    • Strategies therapeutiques et recommendations pour la prise en charge des patients atteints de leucémie myéloide chronique
    • Bories D, Devergie A, Gardempas-Pain M, Kuentz M, Legros L, Mahon FX, et al. Strategies therapeutiques et recommendations pour la prise en charge des patients atteints de leucémie myéloide chronique. Hématologie 2003; 9: 497-512.
    • (2003) Hématologie , vol.9 , pp. 497-512
    • Bories, D.1    Devergie, A.2    Gardempas-Pain, M.3    Kuentz, M.4    Legros, L.5    Mahon, F.X.6
  • 11
    • 0141788346 scopus 로고    scopus 로고
    • STI-571: An anticancer protein-tyrosine kinase inhibitor
    • Roskoski Jr. R. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 2003; 309: 709-17.
    • (2003) Biochem Biophys Res Commun , vol.309 , pp. 709-717
    • Roskoski Jr., R.1
  • 13
    • 0037093092 scopus 로고    scopus 로고
    • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis : Results of a phase II study
    • Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmana OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis : results of a phase II study. Blood 2002; 99: 3530-9.
    • (2002) Blood , vol.99 , pp. 3530-3539
    • Sawyers, C.L.1    Hochhaus, A.2    Feldman, E.3    Goldman, J.M.4    Miller, C.B.5    Ottmana, O.G.6
  • 14
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3    Gathmann, I.4    Baccarani, M.5    Cervantes, F.6
  • 15
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
    • (2001) Science , vol.293 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Rao, P.N.6
  • 16
    • 0037514458 scopus 로고    scopus 로고
    • Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back
    • Von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia- chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17: 829-38.
    • (2003) Leukemia , vol.17 , pp. 829-838
    • Von Bubnoff, N.1    Peschel, C.2    Duyster, J.3
  • 17
    • 4344672552 scopus 로고    scopus 로고
    • Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance
    • Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-31.
    • (2004) Leukemia , vol.18 , pp. 1321-1331
    • Hochhaus, A.1    La Rosee, P.2
  • 18
    • 0036682481 scopus 로고    scopus 로고
    • Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
    • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-8.
    • (2002) Blood , vol.100 , pp. 1014-1018
    • Roche-Lestienne, C.1    Soenen-Cornu, V.2    Grardel-Duflos, N.3    Lai, J.L.4    Philippe, N.5    Facon, T.6
  • 19
    • 0037438467 scopus 로고    scopus 로고
    • Dose escalation of imacinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
    • Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, et al. Dose escalation of imacinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-5.
    • (2003) Blood , vol.101 , pp. 473-475
    • Kantarjian, H.M.1    Talpaz, M.2    O'Brien, S.3    Giles, F.4    Garcia-Manero, G.5
  • 20
    • 11144354274 scopus 로고    scopus 로고
    • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
    • Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-8.
    • (2004) Blood , vol.103 , pp. 2873-2878
    • Kantarjian, H.1    Talpaz, M.2    O'Brien, S.3    Garcia-Manero, G.4    Verstovsek, S.5    Giles, F.6
  • 21
    • 4644341516 scopus 로고    scopus 로고
    • Discontinuation of imatinib therapy after achieving a molecular response
    • Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-5.
    • (2004) Blood , vol.104 , pp. 2204-2205
    • Cortes, J.1    O'Brien, S.2    Kantarjian, H.3
  • 22
    • 18144451171 scopus 로고    scopus 로고
    • Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders
    • Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074-81.
    • (2001) Blood , vol.98 , pp. 3074-3081
    • Bonifazi, F.1    De Vivo, A.2    Rosti, G.3    Guilhot, F.4    Guilhot, J.5    Trabacchi, E.6
  • 25
    • 0141887616 scopus 로고    scopus 로고
    • Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): Study of toxicity and efficacy
    • Michallet AS, Nicolini F, Michallet M. Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy. Bull Cancer 2003; 90: 758-62.
    • (2003) Bull Cancer , vol.90 , pp. 758-762
    • Michallet, A.S.1    Nicolini, F.2    Michallet, M.3
  • 26
    • 20844447330 scopus 로고    scopus 로고
    • Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
    • Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-32.
    • (2004) Blood , vol.104 , pp. 2926-2932
    • Branford, S.1    Rudzki, Z.2    Parkinson, I.3    Grigg, A.4    Taylor, K.5    Seymour, J.F.6
  • 27
    • 10744232328 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    • Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-83.
    • (2003) Blood , vol.102 , pp. 276-283
    • Branford, S.1    Rudzki, Z.2    Walsh, S.3    Parkinson, I.4    Grigg, A.5    Szer, J.6
  • 28
    • 0036090222 scopus 로고    scopus 로고
    • Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
    • Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-25.
    • (2002) Blood , vol.99 , pp. 319-325
    • Graham, S.M.1    Jorgensen, H.G.2    Allan, E.3    Pearson, C.4    Alcorn, M.J.5    Richmond, L.6
  • 29
    • 4544312606 scopus 로고    scopus 로고
    • Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia
    • Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004; 323: 728-30.
    • (2004) Biochem Biophys Res Commun , vol.323 , pp. 728-730
    • Sorel, N.1    Bonnet, M.L.2    Guillier, M.3    Guilhot, F.4    Brizard, A.5    Turhan, A.G.6
  • 30
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
    • (2004) Science , vol.305 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3    Chen, P.4    Norris, D.5    Sawyers, C.L.6
  • 31
    • 4644368478 scopus 로고    scopus 로고
    • Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML
    • O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004; 104: 2532-9.
    • (2004) Blood , vol.104 , pp. 2532-2539
    • O'Hare, T.1    Pollock, R.2    Stoffregen, E.P.3    Keats, J.A.4    Abdullah, O.M.5    Moseson, E.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.